Previous close | 4.5100 |
Open | 4.4800 |
Bid | 4.3000 x 500 |
Ask | 4.3600 x 600 |
Day's range | 4.3100 - 4.5500 |
52-week range | 1.3500 - 6.8500 |
Volume | |
Avg. volume | 737,403 |
Market cap | 255.524M |
Beta (5Y monthly) | 1.45 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.8500 |
Earnings date | 11 May 2024 - 15 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 8.83 |
BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Tuesday, May 14, 2024 at 3:05 PM ET at the RBC Capital Markets Global Healthcare Conference, where members of management will also host investor one-on-one meetings. A live webcast and
BOSTON, March 28, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, reported today that Pyxis Oncology’s Compensation Committee of the Board of Directors granted restricted stock units with respect to an aggregate of 39,680 shares of Pyxis Oncology’s common stock and stock options to purchase an aggregate of 49,600 shares of Pyxis Oncology’s common stock to a newly hired
Non-dilutive funding to support development of first-in-concept lead Antibody-Drug Conjugate (ADC) asset, PYX-201 Pyxis Oncology retains rights to three other antibodies in development by Apexigen’s licensees discovered through the APXiMAB platform BOSTON, March 27, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that it has completed the sale of its rig